Biotech Stocks' Research Reports Released on Ampio Pharma, AmpliPhi Biosciences, Actinium Pharma, and BioPharmX

Thursday, January 25, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, January 25, 2018 /PRNewswire/ -- strives to bring the best free research to the investment

community.  Today we are offering reports on AMPE, APHB, ATNM, and BPMX which can be accessed for free by signing up to On Wednesday, the NASDAQ Composite ended the day at 7,415.06, down 0.61%; the Dow
Jones Industrial Average edged 0.16% higher, to finish at 26,252.12; and the S&P 500 closed at 2,837.54, marginally slipping 0.06%. US markets saw four out of nine sectors finishing the day in green, four in red, and one in neutral territory. has initiated research reports on the following Biotechnology stocks: Ampio Pharmaceuticals Inc. (NYSE AMER: AMPE), AmpliPhi Biosciences Corp. (NYSE AMER: APHB), Actinium Pharmaceuticals Inc. (NYSE AMER: ATNM), and BioPharmX Corp. (NYSE AMER: BPMX). All you have to do is sign up today for this free limited time offer by clicking the link below.

Ampio Pharmaceuticals 

Englewood, Colorado headquartered Ampio Pharmaceuticals Inc.'s stock finished Wednesday's session 0.36% lower at $2.73 with a total trading volume of 648,891 shares. The stock has gained 173.00% over the past three months and 196.45% in the previous twelve months. The Company's shares are trading above their 50-day and 200-day moving averages by 19.33% and 153.37%, respectively. Moreover, shares of Ampio Pharma, which focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the US, have a Relative Strength Index (RSI) of 48.65. Get the full research report on AMPE for free by clicking below at:

AmpliPhi Biosciences 

Shares in San Diego, California headquartered AmpliPhi Biosciences Corp. declined 2.78%, ending yesterday's session at $1.05 with a total trading volume of 271,978 shares. The stock has gained 6.02% in the past month. The Company's shares are trading below their 50-day moving average by 1.30%. Moreover, shares of AmpliPhi Biosciences, which focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology, have an RSI of 46.51.

On January 17th, 2018, research firm H.C. Wainwright reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $5 a share to $6 a share. Gain free access to the research report on APHB at:

Actinium Pharmaceuticals 

On Wednesday, New York-based Actinium Pharmaceuticals Inc.'s stock saw a rise of 1.64%, to close the day at $0.74. A total volume of 431,233 shares was traded. The Company's shares have advanced 10.18% in the last month. The stock is trading above its 50-day moving average by 8.58%. Additionally, shares of Actinium Pharma, which develops targeted payload immunotherapeutics for the treatment of advanced cancers, have an RSI of 58.69. Register for your free report coverage on ATNM at:


Shares in Menlo Park, California headquartered BioPharmX Corp. ended the day 3.91% lower at $0.13. A total volume of 5.37 million shares was traded, which was above their three months average volume of 3.99 million shares. The stock has gained 16.09% in the last month. The Company's shares are trading below their 50-day moving average by 1.03%. Furthermore, shares of BioPharmX, which develops and commercializes novel prescription and over-the-counter products that address dermatology and women's health markets, have an RSI of 54.62. Get the free research report on BPMX at:

Wall St. Equities: 

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: +21-32-044-483 Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Wall St. Equities

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store